Abstract
Despite all the progress in cancer treatment, glioblastoma, the most malignant tumor of the central nervous system, remains a terminal disease and new therapeutic approaches are urgently needed. A combination of chemotherapy with modifications that lower the apoptotic threshold of cancer cells could be effective. Cathepsin L inhibition was suggested as one of such modifications but the mechanism of cathepsin L anti-apoptotic activity is largely unknown. In the present study we show that, in U87 glioblastoma cells, cathepsin L is present in the nucleus and regulates the transcription of effector caspases 3 and 7. In cells with low cathepsin L expression, p53 and prohibitin—transcription factors that regulate caspase 7 expression—accumulate in the nuclei. The importance of p53 in this process is highlighted by the fact that in U87 cells with inhibited p53 transcriptional activity or in p53-negative cells U251, cathepsin L inhibition did not influence caspase 7 expression and had minimal effect on the level of apoptosis. Since p53 pathways are often mutated in glioblastoma, the findings of our study need to be considered before using cathepsin L inhibition for glioblastoma therapy and suggest that such adjuvant therapy may be effective only for a subpopulation of p53 wild type glioblastoma patients.
Similar content being viewed by others
References
Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445–1453
Lopez-Otin C, Matrisian LM (2007) Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7:800–808
Lah TT, Duran Alonso MB, Van Noorden CJ (2006) Antiprotease therapy in cancer: hot or not? Expert Opin Biol Ther 6:257–279
Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D et al (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20:543–556
Lah TT, Kalman E, Najjar D, Gorodetsky E, Brennan P, Somers R, Daskal I (2000) Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis. Hum Pathol 31:149–160
Strojnik T, Kavalar R, Trinkaus M, Lah TT (2005) Cathepsin L in glioma progression: comparison with cathepsin B. Cancer Detect Prev 29:448–455
Rousselet N, Mills L, Jean D, Tellez C, Bar-Eli M, Frade R (2004) Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res 64:146–151
Amuthan G, Biswas G, Ananadatheerthavarada HK, Vijayasarathy C, Shephard HM, Avadhani NG (2002) Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells. Oncogene 21:7839–7849
Zajc I, Sever N, Bervar A, Lah TT (2002) Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines. Cancer Lett 187:185–190
Zajc I, Hreljac I, Lah T (2006) Cathepsin L affects apoptosis of glioblastoma cells: a potential implication in the design of cancer therapeutics. Anticancer Res 26:3357–3364
Gole B, Duran Alonso MB, Dolenc V, Lah T (2009) Post-translational regulation of cathepsin B, but not of other cysteine cathepsins, contributes to increased glioblastoma cell invasiveness in vitro. Pathol Oncol Res 15:711–723
Lankelma JM, Voorend DM, Barwari T, Koetsveld J, Van der Spek AH, De Porto AP, Van Rooijen G et al (2010) Cathepsin L, target in cancer treatment? Life Sci 86:225–233
Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, Ellerby LM et al (2001) Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem 276:3149–3157
Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281:1309–1312
Di Piazza M, Mader C, Geletneky K, Herrero YCM, Weber E, Schlehofer J, Deleu L et al (2007) Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol 81:4186–4198
Levicar N, Dewey RA, Daley E, Bates TE, Davies D, Kos J, Pilkington GJ et al (2003) Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Ther 10:141–151
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174
Torsvik A, Rosland GV, Svendsen A, Molven A, Immervoll H, McCormack E, Lonning PE et al (2010) Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track—letter. Cancer Res 70:6393–6396
Murphy PJ, Galigniana MD, Morishima Y, Harrell JM, Kwok RP, Ljungman M, Pratt WB (2004) Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. J Biol Chem 279:30195–30201
Schuler S, Wenz I, Wiederanders B, Slickers P, Ehricht R (2006) An alternative method to amplify RNA without loss of signal conservation for expression analysis with a proteinase DNA microarray in the ArrayTube format. BMC Genomics 7:144
Pucer A, Castino R, Mirkovic B, Falnoga I, Slejkovec Z, Isidoro C, Lah TT (2010) Differential role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human glioblastoma cells. Biol Chem 391:519–531
Sivaparvathi M, Sawaya R, Wang SW, Rayford A, Yamamoto M, Liotta LA, Nicolson GL et al (1995) Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Exp Metastasis 13:49–56
Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J (2000) Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 486:247–251
Goulet B, Baruch A, Moon NS, Poirier M, Sansregret LL, Erickson A, Bogyo M et al (2004) A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol Cell 14:207–219
Caserman S, Kenig S, Sloane BF, Lah TT (2006) Cathepsin L splice variants in human breast cell lines. Biol Chem 387:629–634
Goulet B, Sansregret L, Leduy L, Bogyo M, Weber E, Chauhan SS, Nepveu A (2007) Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation. Mol Cancer Res 5:899–907
Sullivan S, Tosetto M, Kevans D, Coss A, Wang L, O’Donoghue D, Hyland J et al (2009) Localization of nuclear cathepsin L and its association with disease progression and poor outcome in colorectal cancer. Int J Cancer 125:54–61
Reilly JJ Jr, Mason RW, Chen P, Joseph LJ, Sukhatme VP, Yee R, Chapman HA Jr (1989) Synthesis, processing of cathepsin L, an elastase, by human alveolar macrophages. Biochem J 257:493–498
Hentze H, Latta M, Kunstle G, Lucas R, Wendel A (2003) Redox control of hepatic cell death. Toxicol Lett 139:111–118
Guicciardi ME, Leist M, Gores GJ (2004) Lysosomes in cell death. Oncogene 23:2881–2890
Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S (2003) Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 278:47853–47861
Joshi B, Rastogi S, Morris M, Carastro LM, DeCook C, Seto E, Chellappan SP (2007) Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites. Biochem J 401:155–166
Haupt S, Berger M, Goldberg Z, Haupt Y (2003) Apoptosis - the p53 network. J Cell Sci 116:4077–4085
Zheng X, Chu F, Chou PM, Gallati C, Dier U, Mirkin BL, Mousa SA et al (2009) Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol 296:C65–C74
Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, Saceda M (2004) Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol 180:497–504
Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M (2004) Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23:3541–3549
Zhu DM, Uckun FM (2000) Cathepsin inhibition induces apoptotic death in human leukemia and lymphoma cells. Leuk Lymphoma 39:343–354
Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60:166–193
Huse JT, Holland EC (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10:319–331
Navab R, Pedraza C, Fallavollita L, Wang N, Chevet E, Auguste P, Jenna S et al (2008) Loss of responsiveness to IGF-I in cells with reduced cathepsin L expression levels. Oncogene 27:4973–4985
Wille A, Gerber A, Heimburg A, Reisenauer A, Peters C, Saftig P, Reinheckel T et al (2004) Cathepsin L is involved in cathepsin D processing and regulation of apoptosis in A549 human lung epithelial cells. Biol Chem 385:665–670
Wu GS, Saftig P, Peters C, El-Deiry WS (1998) Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 16:2177–2183
Acknowledgments
The work was supported by Slovenian Research Agency, Programme #P-0105-0245 (granted to TTL), and Young Researcher Project (granted to SK). The authors are thankful to Dr. Viktor Menart for human recombinant TNFα, Dr. Janko Kos for cathepsin L antibody and ELISA assay, Dr. Nobuhiko Katunuma for cathepsin L inhibitor Clik 148 and Dr. Bernd Wiederanders for the DNA-microarray.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
10495_2011_600_MOESM1_ESM.tif
Electronic supplementary material 1: The efficacy of CatL silencing CatL expression was measured at the level of (a) mRNA and (b) enzyme activity in the control and transfected U87 cells. (a): U87 cells transfected with anti-CatL siRNA, non-si RNA and non-transfected control cells were collected with TRIzol reagent at designated times after transfection. CatL expression was determined by qRT-PCR. (b): Cells were collected in a homogenization buffer at designated times, proteins were extracted and enzyme activity tested using fluorescence-labeled substrate Z-Phe-Arg AMC, as decribed in Materials and methods. Results are presented as means of at least three independent experiments ± SD. Expression and activity in non-si cells is set as 1. (TIFF 25 kb)
Rights and permissions
About this article
Cite this article
Kenig, S., Frangež, R., Pucer, A. et al. Inhibition of cathepsin L lowers the apoptotic threshold of glioblastoma cells by up-regulating p53 and transcription of caspases 3 and 7. Apoptosis 16, 671–682 (2011). https://doi.org/10.1007/s10495-011-0600-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10495-011-0600-6